Natixis Advisors LLC Sells 157,161 Shares of GSK plc (NYSE:GSK)

Natixis Advisors LLC lowered its position in GSK plc (NYSE:GSK) by 31.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 343,334 shares of the pharmaceutical company’s stock after selling 157,161 shares during the quarter. Natixis Advisors LLC’s holdings in GSK were worth $11,612,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in GSK. Dorsey & Whitney Trust CO LLC grew its holdings in GSK by 2.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock valued at $389,000 after purchasing an additional 278 shares during the last quarter. Sunbelt Securities Inc. lifted its stake in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Rehmann Capital Advisory Group boosted its holdings in GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after acquiring an additional 332 shares during the period. GC Wealth Management RIA LLC grew its position in GSK by 2.6% in the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock valued at $474,000 after acquiring an additional 353 shares during the last quarter. Finally, Jacobi Capital Management LLC increased its stake in GSK by 3.9% in the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock worth $352,000 after purchasing an additional 389 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

Shares of GSK opened at $39.53 on Thursday. The stock has a market capitalization of $81.81 billion, a PE ratio of 24.86, a PEG ratio of 1.12 and a beta of 0.58. The company has a 50 day moving average price of $36.42 and a 200-day moving average price of $36.98. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 3.98%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.